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Skeletal muscleIntramuscular creatine plays a crucial role in maintaining skeletal muscle energy homeostasis, and its entry into
the cell is dependent upon the sodium chloride dependent Creatine Transporter (CrT; Slc6a8). CrT activity is
regulated by a number of factors including extra- and intracellular creatine concentrations, hormones, changes
in sodium concentration, and kinase activity, however very little is known about the regulation of CrT gene
expression. The present study aimed to investigate how Creatine Transporter (CrT) gene expression is regulated
in skeletal muscle. Within the ﬁrst intron of the CrT gene, we identiﬁed a conserved sequence that includes the
motif recognized by the Estrogen-related receptor α (ERRα), also known as an Estrogen-related receptor
response element (ERRE). Additional ERREs conﬁrming to the known consensus sequence were also identiﬁed
in the region upstream of the promoter. When partnered with peroxisome proliferator-activated receptor-
gamma co-activator-1alpha (PGC-1α) or beta (PGC-1β), ERRα induces the expression of many genes important
for cellular bioenergetics. We therefore hypothesized that PGC-1 and ERRα could also regulate CrT gene expres-
sion and creatine uptake in skeletal muscle. Here we show that adenoviral overexpression of PGC-1α or PGC-1β
in L6 myotubes increased CrT mRNA (2.1 and 1.7-fold, P b 0.0125) and creatine uptake (1.8 and 1.6-fold,
P b 0.0125), and this effect was inhibited with co-expression of shRNA for ERRα. Overexpression of a constitu-
tively active ERRα (VP16-ERRα) increased CrT mRNA approximately 8-fold (P b 0.05), resulting in a 2.2-fold
(P b 0.05) increase in creatine uptake. Lastly, chromatin immunoprecipitation assays revealed that PGC-1α
and ERRα directly interact with the CrT gene and increase CrT gene expression.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Creatine in its free and phosphorylated forms plays a crucial role in
maintaining skeletal muscle energy homeostasis by resynthesizing
ATP [1]. Approximately half of the body's creatine requirement comes
from the diet, and most of the remainder is synthesized via a two-step
process in the kidney and liver [1]. The majority of the body's creatine
is found in skeletal muscle [2]. The importance of skeletal muscle
creatine is demonstrated in mice that are deﬁcient in an essential
enzyme in creatine biosynthesis, L-arginine:glycine amidinotransferase
(AGAT), and show systemic depletion of creatine [3]. These mice
develop severe muscle atrophy, reduced strength and mitochondrial
dysfunction. In contrast, increasing skeletal muscle creatine via supple-
mentation increases muscle strength and mass in healthy subjectsndNutrition Research (C-PAN),
ty, 221 BurwoodHighway 3125,
46017.
sell).undertaking resistance exercise [4, 5], and improves muscle function
in Duchennemuscular dystrophy (DMD) [6], inﬂammatorymyopathies
[7] and mdx mice [8], a rodent model of DMD. The amount of creatine
within a muscle ﬁber is dependent on its uptake into the cell, creatine
trapping, and its degradation into creatinine and subsequent loss from
the cell. Creatine uptake is an important determinant of intramyocyte
creatine levels and occurs via the sodium chloride dependent Creatine
Transporter (CrT, encoded by SLC6A8) [9].
CrT activity is regulated by extra- and intracellular creatine concentra-
tions [10–12], hormones [12], changes in sodium concentrations [13],
kinase activity [14–18], and translocation of the transporter to the
plasma membrane [19, 20]. However, not a lot is known about what
regulates CrT gene expression. Several studies suggest that in rodents
the CrTworks close to saturation [11, 12], and therefore altering the levels
of CrT may be a major determinant of creatine uptake within the cell. In
support of this, CrT mRNA and intracellular creatine levels are reduced
in skeletal muscle of patients with muscular dystrophies, and inﬂamma-
tory, congenital and mitochondrial myopathies [21, 22], suggesting that
increasing CrT gene expression may be an attractive therapeutic target
to increase creatine levels in these conditions.
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gene for conserved regulatory sites and identiﬁed amotif corresponding
to the binding site of the Estrogen-related receptor-α (ERRα) within
the ﬁrst intron of the CrT gene. Two additional ERRα response elements
(ERREs) conﬁrming to the known consensus sequencewere also identi-
ﬁed in the region upstreamof the CrT promoter, ~2.2 kb upstreamof the
transcriptional start site (Fig. 1A & C). ERRα binding sites are commonly
found in many genes involved in oxidative energy metabolism [23–25].
ERRα is a nuclear receptor that acts as a latent transcription factor, and
promotes gene transcription when partnered with co-activators of theFig. 1. Graphic representation of the Estrogen-related receptor response elements (ERREs) loca
intron ERREs. (B) The ERREwithin theﬁrst intron of the Creatine Transporter (CrT) gene. The gra
upstream of the transcriptional start site. Black bars indicate regions matching the ERRE conse
Source: University of California, Santa Cruz, genome browser.peroxisome proliferator-activated receptor γ, coactivator-1 (PGC-1)
family, such as PGC-1α and PGC-1β. In skeletal muscle, PGC-1α and
PGC-1β regulate the expression of many genes involved in energy me-
tabolism and substrate oxidation [26], and many of these effects are
dependent on ERRα [25, 27–29]. In particular, PGC-1α and PGC-1β,
when partnered with ERRα, regulate the uptake of two major fuel
sources in skeletal muscle; glucose and fatty acids. Overexpression of
PGC-1α or PGC-1β in rodent skeletalmuscle results in increased expres-
sion of the glucose transporter type 4 (GLUT4), with parallel increases in
insulin-stimulated glucose transport [30, 31]. Similarly, PGC-1α andted at the CrT (Slc6a8) locus. (A) An overview of the CrT gene showing upstream and ﬁrst
ph represents conservation across vertebrate species. (C) Two ERREs approximately 2.2 kb
nsus sequence (T/C NAAGGTCA).
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well as many genes associated with fat oxidation in skeletal muscle
[27, 30, 32, 33]. As creatine is also an important substrate for muscle
energy homeostasis, we hypothesized that PGC-1α/ERRα or PGC-
1β/ERRα also regulates expression of the CrT, and therefore creatine
uptake, in skeletal muscle. The present study aimed to determine if
PGC-1α/ERRα and/or PGC-1β/ERRα can increase the expression of
the CrT gene and creatine uptake in L6 myotubes.
2. Materials and methods
2.1. Cell culture
L6 myoblasts (American type culture collection; ATCC, Manassas,
VA) were incubated at 37 °C with 5% CO2, in high-glucose DMEM
supplementedwith 10% FBS, 100U/ml penicillin and100 μg/ml strepto-
mycin (Invitrogen, Carlsbad, CA). Myoblasts were plated at a density of
2 × 104/cm2 in 12-well plates. Upon conﬂuence (~48 h), medium was
changed to high-glucose DMEM supplemented with 2% horse serum
(Invitrogen), 100 U/ml penicillin and 100 μg/ml streptomycin for
5 days until multinucleated myotubes had formed. For CrT siRNA
experiments, medium without penicillin or streptomycin was used.
Medium was replaced every 48 h.
2.2. Transfections/infections
2.2.1. CrT knockdown combined with PGC-1α and PGC-1β overexpression
Myotubeswere transfectedwith 60 pmol pre-designed Stealth RNAi
™ short interfering RNA (siRNA) for the CrT (Slc6A8) (cat no.
RSS328932 and RSS328934) or the Stealth RNAi siRNA Negative
Control Medium GC (scramble siRNA; Invitrogen). Transfections were
performed using 2 μL/well Lipofectamine 2000 Transfection Reagent
diluted in Opti-MEM Reduced Serum Medium (Invitrogen) on day 5
of differentiation. After 24 h, myotubes were washed and infected
with adenoviruses expressing green ﬂuorescent protein (GFP), PGC-
1α or PGC-1β using a multiplicity of infection (MOI) of 100. Myotubes
were harvested on day 8 for RNA, protein and creatine uptake assays.
2.2.2. ERRa knockdown combinedwith PGC-1α and PGC-1β overexpression
Myotubes were infected with an adenovirus expressing shRNA for
ERRα (AdshERRα) or its control, AdSUPER, using an MOI 200 on day 5
of differentiation [23]. After 24 h,myotubes were infectedwith an addi-
tional dose of AdshERRα (or its control vector), as well as GFP, PGC-1α
or PGC-1β at anMOI of 100. Cells were harvested on day 8 of differenti-
ation for RNA, protein and creatine uptake assays.
2.2.3. Constitutively active ERRα
Myotubes were infected on day 5 of differentiationwith an adenovi-
rus expressing ERRαwith a heterologous strong transcriptional activa-
tion domain, VP16-ERRα, or its control VP16-control, using an MOI of
100 [28]. Cells were harvested on day 7 of differentiation for RNA,
protein, and creatine uptake assays.
2.3. Messenger RNA (mRNA) expression
2.3.1. RNA extraction
RNA was extracted using Tri-Reagent solution (Ambion Inc.,
Austin, TX). RNA concentrations were determined using the NanoDrop
2000 (NanoDrop products, Wilmington, DE). RNA was reverse tran-
scribed to cDNA using a High Capacity cDNA reverse transcription kit
(Applied Biosystems, Forster City, CA).
2.3.2. Real-time PCR
Real-time PCR was performed using a Stratagene Mx3000P QPCR
System and the MxPro QPCR software (Stratagene, La Jolla, CA). Cycling
conditions for the real-time PCR consisted of one denaturing cycle at95 °C for 2 min, followed by 40 cycles of denaturing at 95 °C for 5 s
and annealing at 60 °C for 20 s, and elongation at 72 °C for 60 s. A disso-
ciation curve was generated to show that only one product had been
ampliﬁed during the PCR. Each 20 μL reaction contained 0.5× Power
SYBR Green PCR Master Mix (Applied Biosystems), 25 ng of cDNA, and
the forward (F) and reverse (R) primers for the gene of interest. Primers
for CrT (Forward: 5′CTGTCTCCTCAGGGCAAAAG and Reverse: 5′CTAA
AGCTGGGGCTGCTATG) and 36B4 (Forward: 5′CCAGAGGTGCTGGACA
TCACAGAG and Reverse: 5′TGGAGTGAGGCACTGAGGCAAC) were
designed using Primer 3 (www.primer3.sourceforge.net) and the
sequences cross checked for gene speciﬁcity using a BLAST search
(www.ncbi.nlm.gov/BLAST). Primers were synthesized by Gene Works
(Adelaide, SA). To compensate for variations in input RNA amounts
and efﬁciency of the reverse transcription, data was normalized to
ribosomal protein, 36B4 (also known as RPLPO) mRNA.
2.4. Creatine uptake assay
Creatine uptake was determined by measuring the incorporation
of [14C]-Creatine (American Radiolabeled Chemicals, St Louis, MO)
into the myotubes. During the last hour of adenoviral infections,
myotubes were incubated in creatine uptake buffer consisting of
DMEM with 2% FBS (Invitrogen), 100 μM creatine (Sigma-Aldrich),
and 1 μCi/ml [14C]-Creatine. To stop the reaction, myotubes were
washed in PBS and lysed in 500 μL 0.5 N NaOH/0.1% Triton X-100
(Sigma-Aldrich). Samples were mixed with Ultima Gold scintillation
liquid (Perkin Elmer, Boston, MA) and the uptake of [14C]-Creatine
was measured using a Wallac 1409 DSA liquid scintillation counter
(Perkin Elmer). Counts were normalized to protein content deter-
mined via the BCA Protein Assay Kit (Pierce Biotechnology).
2.5. Chromatin immunoprecipitation (ChIP)
2.5.1. Cell culture and adenoviral infections
C2C12 myoblasts were maintained in DMEM with 10% FBS
(Invitrogen, Carlsbad, CA) at 37 °C with 5% CO2. Conﬂuent myoblasts
were differentiated into myotubes by the addition of DMEMwith 2%
horse serum (Invitrogen). Adenoviruses expressing LacZ, FLAG-
tagged PGC-1α, ERRα, and short hairpin RNA (shRNA) for GFP and
ERRα have been described previously [23, 34]. Myotubes were in-
fected on day 4 of differentiation with adenoviruses expressing
shRNAs (at MOI 50), and on day 6 of differentiation with adenovi-
ruses expressing LacZ (control) and FLAG-PGC-1α (at MOI 50),
together with a second dose of shRNA-expressing adenoviruses
(at MOI 25). The cells were harvested 24 h later.
2.5.2. ChIP assay
ChIP assays were performed with adenovirus-infected C2C12
myotubes as described previously [35]. C2C12 myotubes were
cross-linked for 10 min at 37° in 1% formaldehyde in PBS. After
quenching, sonication to ~500 bp fragments, and pre-clearing by
treatment with protein A/G sepharose, soluble chromatin was
immunoprecipitated with the following antibodies: anti-GFP
(control), anti-FLAG (clone M2) for the detection of FLAG-Tagged
PGC-1α, or anti-ERRα (Epitomics, Burlingame, CA). Genomic DNA
in the immunopuriﬁed complex was quantiﬁed by real-time PCR
using CrT primers: Forward: 5′CCTCTGTCCAAGGTCACACA and
Reverse: 5′TCTGCACAGGATCAGCTTTC, to amplify the ﬁrst intron
region that has the conserved ERRE, as well as Forward: 5′GGATCC
CATGGAATCAGGTCTT and Reverse: 5′GGCAACTGGGAAACAGAAAT
CA, to amplify the ERRE-containing region ~2.2 kb upstream of
the transcriptional start site. Positive (established ERRα binding
genomic sites) and a negative control region are in Ref. [36]. Data
were normalized to total genomic DNA input and expressed relative
to the levels of immunoprecipitated DNA in the anti-GFP control
samples.
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Statistical analyses were performed using either a t-test or a two-
way ANOVA (Prism, GraphPad Software, La Jolla, CA). Multiple t-tests
were used for post-hoc analysis to determine differences between
groups if signiﬁcant interactions were found. The level of signiﬁcance
was set at P b 0.05 for paired t-test analysis, while a Bonferroni adjust-
ment was used for the two-way ANOVA reducing the level of signiﬁ-
cance to P b 0.0125. Comparisons between PGC-1α and PGC-1β
groups have not beenmade. All data are presented asmean± standard
error of the mean (SEM), unless otherwise stated.
3. Results
3.1. PGC-1α and PGC-1β increase CrT mRNA and creatine uptake
To investigate the effect of PGC-1α and PGC-1β on CrT mRNA and
creatine uptake, L6myotubes were infectedwith adenoviruses express-
ing GFP (control), PGC-1α or PGC-1β and co-transfected with CrT
siRNA. Western blot images conﬁrming PGC-1α and PGC-1β overex-
pression, aswell as the expected induction of oxidative phosphorylation
(OXPHOS) genes, are shown in Supplementary Fig. 1A–D. Transfection
with CrT siRNA decreased CrT mRNA by approximately 50% in the GFP
samples (Fig. 2A). Expression of PGC-1α and PGC-1β increased CrT
mRNA by 2.1- and 1.7-fold, respectively, and this was prevented with
the co-transfection of CrT siRNA.
To determine the functional signiﬁcance of the increase in CrT
mRNA, creatine uptake was measured in these cells. PGC-1α and PGC-
1β overexpression increased creatine uptake by 1.8- and 1.6-fold,
respectively, when compared to GFP (Fig. 2B). Similar to the expression
of CrT mRNA, co-transfection with CrT siRNA reduced creatine
uptake by 40% in the GFP samples and prevented the PGC-1α- and
PGC-1β-induced increase in creatine uptake.
3.2. PGC-1α and PGC-1β increase CrT and creatine uptake via ERRα
As we identiﬁed ERREs within the CrT gene (Fig. 1), we next investi-
gated whether ERRα was required for PGC-1α or PGC-1β to increase
CrT mRNA and creatine uptake. To knockdown ERRα, L6 myotubes
were infected with adenoviruses expressing shERRα (AdshERRα)
or the control vector, AdSUPER, followed by overexpression of GFP,
PGC-1α or PGC-1β. As expected [23, 25], PGC-1α and PGC-1β overex-
pression signiﬁcantly increased ERRα protein (~2-fold), while
AdshERRα reduced ERRα protein by 75% in the GFP samples, and 65%
in the PGC-1α or PGC-1β samples (Supplementary Fig. 2). Suppression
of ERRα (AdshERRα) also reduced CrT mRNA by 25% in the GFP
samples, and prevented the increase in CrT mRNA that was seen with
PGC-1α and PGC-1β overexpression (Fig. 3A). Suppression of ERRα
had no effect on basal creatine uptake (GFP) but prevented theFig. 2. CrTmRNA and creatine uptake in L6myotubes overexpressing PGC-1α or PGC-1β, in com
siRNA on day 5 of differentiation, followed by infectionwith GFP, PGC-1α or PGC-1β adenovirus
normalized to 36B4mRNA. n= 5 per group. (B) Creatine uptake, measured by [14C]-creatine in
fold-change (FC) from GFP scramble siRNA. *P b 0.0125 compared to GFP scramble siRNA; #PPGC-1α- and PGC-1β-induced increase in creatine uptake (Fig. 3B).
These results show that ERRα is required for PGC-1α or PGC-1β to
increase CrT mRNA and creatine uptake in L6 myotubes.
3.3. Constitutively active ERRα increases CrT mRNA and creatine uptake
To further support the role of ERRα in the regulation of creatine
uptake, L6 myotubes were infected with adenoviruses expressing a
constitutively active form of ERRα (VP16-ERRα) or its control (VP16-
control). Infection with VP16-ERRα increased endogenous ERRα
protein expression almost 4-fold (Supplementary Fig. 3). VP16-ERRα
increased CrT mRNA by approximately 8-fold (Fig. 4A), and resulted in
a 2.2-fold increase in creatine uptake compared to the VP16-control
myotubes (Fig. 4B).
3.4. ERRα is essential for recruitment of PGC-1α to the CrT gene
To determine whether ERRα and PGC-1α interact physically with
the CrT gene, ChIP was performed, testing binding at two different
sites: the ﬁrst intron that has the conserved ERRE, and the region
~2.2 kb upstream of the transcriptional start site that includes the two
putative ERREs (Fig. 1). To determine binding of endogenous ERRα
and exogenous adenovirally-expressed PGC-1α at these regions,
cross-linked chromatin was immunoprecipitated with antibodies
against GFP (control antibody measuring background), FLAG-tagged
PGC-1α, or ERRα, and the enrichment of the CrT locus DNA in the
immunoprecipitated material was measured. Both PGC-1α and ERRα
were detected at the CrT locus at both positions (Fig. 5A & B), although
the level of binding was higher in the upstream region (Fig. 5B). ERRα
was detected at the CrT locus only when PGC-1α was expressed, i.e.
when endogenous ERRα levels were induced. Knockdown of endoge-
nous ERRα expression by shRNA ablated binding of PGC-1α to the CrT
locus, demonstrating a critical role for ERRα in recruitment of the
PGC-1α coactivator to the CrT gene.
4. Discussion
Currently, very little is known about how CrT gene and protein
expression are regulated. In skeletal muscle, PGC-1α and PGC-1β
regulate the expression of many genes involved in energy metabolism
via the transcription factor ERRα [26], and we have identiﬁed a
conserved ERRE in the ﬁrst intron of the CrT gene, as well as two
upstream ERREs. It was therefore of interest to determine whether the
PGC-1/ERR transcriptional pathway may also regulate CrT expression
and creatine uptake, which are critical to maintaining cellular energy
homeostasis. Here we show for the ﬁrst time that overexpression of
PGC-1α or PGC-1β increases CrT mRNA as well as creatine uptake into
L6 myotubes. This effect is dependent on ERRα. We also show that
PGC-1α gets recruited to the CrT promoter by ERRα.binationwith CrT siRNA.Myotubes were transfectedwith either control (scramble) or CrT
es on day 6. Sampleswere harvested on day 8 of differentiation. (A) CrTmRNA expression,
corporation on the ﬁnal day. n= 6 per group, repeated in 3 experiments. Data represents
b 0.0125 compared to scramble siRNA for each adenovirus.
Fig. 3. CrT mRNA and creatine uptake in L6 myotubes infected with AdshERRα and PGC-1 adenoviruses. Myotubes were infected with either AdSUPER or AdshERRα at day 5 of
differentiation, followed by infection with GFP, PGC-1α or PGC-1β and an additional dose of AdSUPER and AdshERRα, at day 6. Samples were harvested on day 8 of differentiation. (A) CrT
mRNA expression, normalized to 36B4 mRNA expression. n = 6 per group (B) Creatine uptake, measured by [14C]-creatine incorporation during the last hour of infection. n = 6 per group,
repeated in 3 experiments. Data represents fold-change (FC) from GFP AdSUPER. *P b 0.0125 compared to GFP AdSUPER; #P b 0.0125 compared to AdSUPER for each adenovirus.
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be regulated by extra and intracellular creatine concentrations
[10–12], hormones [12], changes in sodium concentrations [13],
kinase activity [14–18], and its translocation to the plasma mem-
brane [19, 20]. However the direct molecular mechanisms responsible
for these effects are unknown. Here we show that the transcriptional
pathway involving PGC-1α, PGC-1β and ERRα can increase the
expression of the CrT gene resulting in increased creatine uptake. It
is possible that the PGC-1/ERRα pathway mediates some of the
above responses. For example, depletion of intracellular creatine by
β-Guanidinopropionic acid (β-GPA), a competitive inhibitor of the
CrT, results in increased creatine uptakewhen re-exposed to high levels
of creatine [10]. In rodent skeletal muscle, β-GPA increases PGC-1α and
PGC-1βmRNA [37], suggesting that the β-GPA induced stimulation of
PGC-1α and PGC-1β expression may lead to increased CrT levels and
creatine uptake. β-GPA treatment also results in a compensatory
increase in oxidative phosphorylation [38, 39], further supportingFig. 4. CrT mRNA and creatine uptake in L6 myotubes infected with VP16-ERRα.
Myotubes were infected with either control (VP16-control) or constitutively active
ERRα (VP16-ERRα) on day 5 of differentiation. Samples were harvested on day 7 of
differentiation. (A) CrT mRNA expression, normalized to 36B4 mRNA. n = 6 per
group. (B) Creatine uptake, measured by [14C]-creatine incorporation for one hour
on the ﬁnal day. n = 6 per group, repeated in 3 experiments. Data represents
fold-change (FC) from VP16-control. *P b 0.01 compared to VP16-control.increased PGC-1α and/or PGC-1β activity in response to depletion of
intracellular creatine. In contrast to this, we did not observe changes
in PGC-1α or PGC-1β protein, or OXPHOS gene expression, in response
to knockdown of CrT mRNA in this study. However it is likely that the
~50% reduction in CrT mRNA using this method does not result in the
critically low intracellular creatine levels that are seen with β-GPA
treatment. Further studies are required to test these hypotheses.
PGC-1α and ERRα may also be involved in the increased creatine
uptake in response to some kinases. For example, AMPK stimulates
creatine uptake and increases CrT mRNA in cardiomyocytes [15]. This
effect is indirect, as the CrT protein does not contain phosphorylation
sites for this kinase. In skeletal muscle, AMPK is a well-known regulator
of PGC-1α activity [40, 41], and therefore PGC-1α/ERRαmay mediate
the increase in creatine uptake in response to AMPK activation. This
possibility also remains to be tested. Lastly, a recent publication shows
that CrT gene expression is increased in intestinal epithelial cells
under hypoxic conditions [42]. Interestingly, hypoxia is known to
induce PGC-1α activity in cultured muscle cells and skeletal muscle
in vivo [43], and therefore PGC-1αmay increase CrT expression under
such conditions.
In skeletal muscle, PGC-1α and PGC-1β induce the expression of
many genes involved in energymetabolism andmitochondrial function
via their co-activation of ERRα [25, 28]. Here we show that ERRα is also
required for PGC-1α or PGC-1β to increase CrT mRNA and creatine
uptake in L6 myotubes. Knockdown of ERRα did not affect creatine
uptake under basal conditions (i.e. in the GFP-infected cells), despite a
25%decrease in CrTmRNA. Aswewere unable tomeasure protein levels
of the CrT, it is likely that a 25% reduction in CrTmRNAwasnot sufﬁcient
to reduce CrT protein levels. Further supporting the role of ERRα in
creatine uptake, the overexpression of a constitutively active ERRα
increased CrT mRNA and creatine uptake.
ERRα induces gene expression by binding to ERREs in regulatory
regions of target genes when co-activated by PGC-1α or PGC-1β [23].
Here we show that PGC-1α and ERRα interact directly with the
CrT gene. Supporting our current ﬁndings, previous studies using
ChIP-on-ChIP analysis has identiﬁed the CrT (Slc6a8) as an ERRα
target gene in the kidney [44], and in liver cells [45]. Interestingly,
we observe that PGC-1α and ERRα binding is greater in the non-
conserved upstream region of the CrT rather than the evolutionary
conserved ERRE within the ﬁrst intron. This ﬁnding ﬁts recent obser-
vations showing that transcription factor binding is often more
common on species-speciﬁc sites rather than the evolutionary
conserved ones [46]. Notably, many of the non-conserved binding
sites often show evidence of nearby similar binding events in other
species [46]. Indeed, the human CrT gene also contains a putative
ERRE at ~1.6 kb upstream of its transcriptional start site, and therefore
it is likely that PGC-1/ERRα interact similarly with the human CrT gene.
To our knowledge, this is the ﬁrst study to identify potential
transcriptional regulators of the CrT gene in skeletal muscle. This is
Fig. 5. PGC-1α and ERRα bind the CrT gene. ChIPs were performed using antibodies against GFP (control), FLAG (PGC-1α) and ERRα, in C2C12 myotubes infected with adenoviruses
expressing LacZ (control) or PGC-1α, in the absence (shGFP) or presence of shRNA for ERRα (shERRα). (A) Relative occupancy at the region of the ﬁrst intron CrT ERRE, and
(B) relative occupancy at the region of the upstream CrT ERRE. The abundance of CrT DNA is expressed as relative fold-change (FC) to levels in the control, GFP samples. Data are
mean ± SD. n = 5, repeated in two experiments.
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pression, as the CrT promoter also contains potential binding sites
for many other transcription factors. However, these novel ﬁndings
provide insight into potential molecular targets to increase creatine
uptake in skeletal muscle, which may assist in the treatment of
patients suffering from myopathies characterized by decreased CrT
and intracellular creatine levels. These ﬁndings may also have impli-
cations for chronic diseases characterized by decreased skeletal
muscle PGC-1α or PGC-1β expression and impaired metabolism.
For example, PGC-1α and/or PGC-1β are decreased in skeletal
muscle of patients with heart failure [47, 48], chronic obstructive
pulmonary disease (COPD) [49] and type 2 diabetes [50–52].
Interestingly, decreased skeletal muscle creatine levels have been
reported in chronic heart failure [53] and severe COPD [54], while
decreased phosphocreatine is observed in skeletal muscle of type 2
diabetic patients [55]. However, these ﬁndings are not always
consistent, as other studies have observed no difference in skeletal
muscle creatine in heart failure [56] or phosphocreatine in type 2
diabetes [57]. To our knowledge there are currently no studies that
have measured CrT levels in skeletal muscle of these patients, but
would be an interesting area for future research. Our observations
here open up a new avenue by which skeletal muscle creatine levels
may be regulated under pathological conditions characterized by
impaired muscle function and metabolism.
Lastly, the ﬁndings from this study may also have implications in
other tissues that have high creatine requirements. For example,
intracellular creatine and creatine uptake are reduced in rat cardiac
muscle during heart failure [58], while constitutive overexpression of
the CrT in the heart of mice protects against myocardial ischemia [59].
Interestingly, PGC-1α and ERRα mRNA are also decreased in cardiac
muscle during chronic heart failure [47, 60]. These studies, together
with our observations, present the PGC-1/ERRα transcriptional regula-
tion of the CrT gene as an attractive therapeutic target for heart failure.
Whether this may be contributing to the decreased intracellular
creatine requires further investigation.
In summary, this study has shown for the ﬁrst time that overexpres-
sion of the transcriptional coactivators PGC-1α and PGC-1β increases
CrT mRNA and creatine uptake in L6 myotubes in an ERRα-dependent
manner. It also shows that PGC-1α, when partneredwith ERRα, directly
binds to the CrT locus resulting in increased CrT mRNA levels. Further
studies are required to determine if PGC-1β also acts in this manner.
Identiﬁcation of this transcriptional pathway in the regulation of
creatine uptake in skeletal muscle may present a new therapeutic
gene target to increase intracellular creatine levels andmaintain cellular
energy homeostasis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.08.010.Acknowledgements
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